diroximel fumarate (Pending FDA Approval)

Brand and Other Names:Vumerity
  • Print

Dosing & Uses

Multiple Sclerosis

Pending FDA approval for relapsing/remitting forms of multiple sclerosis (MS)

Next:

Pharmacology

Mechanism of Action

Diroximel fumarate is designed to rapidly convert to monomethyl fumarate in the body and may have the potential to offer differentiated GI tolerability due to its chemical structure as compared to dimethyl fumarate

Fumarate has been shown activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, a transcription factor encoded by the NFE2L2 gene

The Nrf2 antioxidant response pathway is a cellular defense against oxidative stress

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.